Welcome!

News Feed Item

Global Antibody Drug Conjugate Market Outlook 2018

NEW YORK, March 17, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Antibody Drug Conjugate Market Outlook 2018
http://www.reportlinker.com/p02048454/Global-Antibody-Drug-Conjugate-Market-Outlook-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

The ADC technology is not new. It dates back to the 90s. However, several issues such as specificity of the payload (drug), and poor conjugation of drug and antibody proved a setback. But, the past few years have witnessed ADCs make a glorious comeback. This can be attributed to the significant advancements that have been made in the field of linker technology as well as payload efficacy and specificity. There are currently two ADC products in the market, Adcetris and Kadcyla.

According to our report, "Global Antibody Drug Conjugate Market Outlook 2018", backed by improved understanding and better technology, the ADC market is anticipated to reach US$ 3.45 Billion by 2018. Our report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved. These drugs will take some time in order to capture their entire potential market.

The report also provides an insight into the key ADCs that are currently in pipeline. At present, only one drug, Inotuzumab Ozogamicin is in late stage clinical trial. Apart from new drug candidates, previously approved drugs are also in late stage trials for other indications. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided. These activities are aimed at combining technologies and capabilities of other companies with inherent ones for the development of ADCs.

Major drivers such as advances in linker technology and patent fencing through ADC development have been discussed. In an attempt to protect their innovative blockbuster drugs, many pharma giants are moving towards ADCs. These moves are going to have a major impact in shaping the ADC market in the coming years. On the other hand, challenges such as the high cost of production of ADCs; difficult upstream and downstream processing; safety considerations etc., will have to be taken care of.

At the end, major players of the ADC market have been discussed. A brief business overview of every player has been provided along with their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has also been done. Whereas on one hand, a player is experienced owing to previously approved ADC, on the other it has licensed ADC technology from top providers. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
1. Analyst View
2. Research Methodology
3. Antibody Drug Conjugate (ADC) - An Introduction
4. ADC Market Outlook to 2018
4.1 Adcetris
4.1.1 Market Potential
4.1.2 Market Size and Forecasts to 2018
4.2 Kadcyla
4.2.1 Market Potential

4.2.2 Market Size and Forecasts to 2018
5. Current Status and Potential of Key ADC in Pipeline
5.1 Inotuzumab Ozogamicin/CMC-544 - Pfizer
5.2 Glembatumumab Vedotin/CDX-011 - Celldex Therapeutics
5.3 SAR-3419 - Sanofi
5.4 PSMA-ADC - Progenics Pharmaceuticals
5.5 RG-7596 - Roche
5.6 RG-7593 - Roche
6. Strategic Collaborations in the ADC Industry
7. Drivers and Challenges
8. Competitive Landscape
8.1 Roche
8.2 Sanofi
8.3 Progenics
8.4 Seattle Genetics
8.5 Celldex Therapeutics

List of Figures

Figure 3 1: ADC - Mechanism of Action
Figure 4 1: Global - ADC Market (Million US$), 2013 & 2018
Figure 4 2: Global - Adcetris Market (Million US$), 2011 & 2012
Figure 4 3: Global - Adcetris Market (Million US$), 2013 & 2018
Figure 4 4: Global - Kadcyla Market (Million US$), 2013 & 2018

List of Tables

Table 4 1: Potential Patients for Adcetris (2012)
Table 4 2: Ongoing Trials for Adcetris
Table 4 3: Potential Patients for Kadcyla (2012)
Table 4 4: Ongoing Trials for Kadcyla
Table 5 1: ADCs in Pipeline
Table 6 1: Strategic Collaborations in the ADC Industry
Table 8 1: Roche - ADCs in Pipeline
Table 8 2: Roche - Strengths and Weaknesses
Table 8 3: Sanofi - ADCs in Pipeline
Table 8 4: Sanofi - Strengths and Weaknesses
Table 8 5: Progenics - ADCs in Pipeline
Table 8 6: Progenics - Strengths and Weaknesses
Table 8 7: Seattle - ADCs in Pipeline
Table 8 8: Seattle Genetics - ADC Collaborator Pipeline
Table 8 9: Seattle - Strengths and Weaknesses
Table 8 10: Celldex Therapeutics - ADC Pipeline
Table 8 11: Celldex Therapeutics - Strengths and Weaknesses

To order this report: Global Antibody Drug Conjugate Market Outlook 2018
http://www.reportlinker.com/p02048454/Global-Antibody-Drug-Conjugate-Market-Outlook-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, shared examples from a wide range of industries – including en...
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
In his session at @DevOpsSummit at 20th Cloud Expo, Kelly Looney, director of DevOps consulting for Skytap, showed how an incremental approach to introducing containers into complex, distributed applications results in modernization with less risk and more reward. He also shared the story of how Skytap used Docker to get out of the business of managing infrastructure, and into the business of delivering innovation and business value. Attendees learned how up-front planning allows for a clean sep...
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
Detecting internal user threats in the Big Data eco-system is challenging and cumbersome. Many organizations monitor internal usage of the Big Data eco-system using a set of alerts. This is not a scalable process given the increase in the number of alerts with the accelerating growth in data volume and user base. Organizations are increasingly leveraging machine learning to monitor only those data elements that are sensitive and critical, autonomously establish monitoring policies, and to detect...
Enterprise architects are increasingly adopting multi-cloud strategies as they seek to utilize existing data center assets, leverage the advantages of cloud computing and avoid cloud vendor lock-in. This requires a globally aware traffic management strategy that can monitor infrastructure health across data centers and end-user experience globally, while responding to control changes and system specification at the speed of today’s DevOps teams. In his session at 20th Cloud Expo, Josh Gray, Chie...
To get the most out of their data, successful companies are not focusing on queries and data lakes, they are actively integrating analytics into their operations with a data-first application development approach. Real-time adjustments to improve revenues, reduce costs, or mitigate risk rely on applications that minimize latency on a variety of data sources. Jack Norris reviews best practices to show how companies develop, deploy, and dynamically update these applications and how this data-first...
Intelligent Automation is now one of the key business imperatives for CIOs and CISOs impacting all areas of business today. In his session at 21st Cloud Expo, Brian Boeggeman, VP Alliances & Partnerships at Ayehu, will talk about how business value is created and delivered through intelligent automation to today’s enterprises. The open ecosystem platform approach toward Intelligent Automation that Ayehu delivers to the market is core to enabling the creation of the self-driving enterprise.
"At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We're here to tell the world about our cloud-scale infrastructure that we have at Juniper combined with the world-class security that we put into the cloud," explained Lisa Guess, VP of Systems Engineering at Juniper Networks, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., discussed how these tools can be leveraged to develop a lasting competitive advantage ...
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
"We're a cybersecurity firm that specializes in engineering security solutions both at the software and hardware level. Security cannot be an after-the-fact afterthought, which is what it's become," stated Richard Blech, Chief Executive Officer at Secure Channels, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.